These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33999716)

  • 1. Non-Small-Cell Lung Cancer Regression by siRNA Delivered Through Exosomes That Display EGFR RNA Aptamer.
    Li Z; Yang L; Wang H; Binzel DW; Williams TM; Guo P
    Nucleic Acid Ther; 2021 Oct; 31(5):364-374. PubMed ID: 33999716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-EGFR ScFv functionalized exosomes delivering LPCAT1 specific siRNAs for inhibition of lung cancer brain metastases.
    Jiang J; Lu Y; Chu J; Zhang X; Xu C; Liu S; Wan Z; Wang J; Zhang L; Liu K; Liu Z; Yang A; Ren X; Zhang R
    J Nanobiotechnology; 2024 Apr; 22(1):159. PubMed ID: 38589859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
    McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
    Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small interfering RNA-mediated suppression of serum response factor, E2-promotor binding factor and survivin in non-small cell lung cancer cell lines by non-viral transfection.
    Walker T; Nolte A; Steger V; Makowiecki C; Mustafi M; Friedel G; Schlensak C; Wendel HP
    Eur J Cardiothorac Surg; 2013 Mar; 43(3):628-33; discussion 633-4. PubMed ID: 23152437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal long non-coding RNA SOX2 overlapping transcript enhances the resistance to EGFR-TKIs in non-small cell lung cancer cell line H1975.
    Zhou D; Xia Z; Xie M; Gao Y; Yu Q; He B
    Hum Cell; 2021 Sep; 34(5):1478-1489. PubMed ID: 34244990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy.
    Garbuzenko OB; Kuzmov A; Taratula O; Pine SR; Minko T
    Theranostics; 2019; 9(26):8362-8376. PubMed ID: 31754402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
    Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
    Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway.
    Taverna S; Pucci M; Giallombardo M; Di Bella MA; Santarpia M; Reclusa P; Gil-Bazo I; Rolfo C; Alessandro R
    Sci Rep; 2017 Jun; 7(1):3170. PubMed ID: 28600504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression.
    Pi F; Binzel DW; Lee TJ; Li Z; Sun M; Rychahou P; Li H; Haque F; Wang S; Croce CM; Guo B; Evers BM; Guo P
    Nat Nanotechnol; 2018 Jan; 13(1):82-89. PubMed ID: 29230043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping.
    Zheng Z; Li Z; Xu C; Guo B; Guo P
    J Control Release; 2019 Oct; 311-312():43-49. PubMed ID: 31446085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
    Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
    Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer.
    Reda M; Ngamcherdtrakul W; Gu S; Bejan DS; Siriwon N; Gray JW; Yantasee W
    Cancer Lett; 2019 Dec; 467():9-18. PubMed ID: 31563561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum exosomal microRNAs as predictive markers for EGFR mutations in non-small-cell lung cancer.
    Xia J; Luo M; Dai L; Wang L; Wang L; Zhu J
    J Clin Lab Anal; 2021 May; 35(5):e23743. PubMed ID: 33682961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
    Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
    Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A targeted siRNA-loaded PDL1-exosome and functional evaluation against lung cancer.
    Lin X; Lin L; Wu J; Jiang W; Wu J; Yang J; Chen C
    Thorac Cancer; 2022 Jun; 13(11):1691-1702. PubMed ID: 35545838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.
    Ahmad A; Maitah MY; Ginnebaugh KR; Li Y; Bao B; Gadgeel SM; Sarkar FH
    J Hematol Oncol; 2013 Oct; 6(1):77. PubMed ID: 24199791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Non-Small Cell Lung Cancer Cells.
    Day TF; Kallakury BVS; Ross JS; Voronel O; Vaidya S; Sheehan CE; Kasid UN
    Mol Cancer Res; 2019 May; 17(5):1207-1219. PubMed ID: 30647104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.